SONN News and Press, Sonnet BioTherapeutics Holdings Inc.

A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.5% to $130.78 on volume of 504,910,586 shares Nikola Corporation (NKLA) fell 31.5% to $0.3296 on volume of 265,124,783 shares SMX (Security Matters) Public Limited Company (SMX) rose 35.1% to $0.1608 o...

PRINCETON, N.J., June 20, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the entry into a definitive agreement for the immed...

Sonnet discovered and characterized a modified version of Interleukin-18 (IL-18 Binding Protein Resistant or IL-18 BPR ) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 Binding Protein (IL-18BP) ...

PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that the SB221 study of SON-1010 (recombinant human Interleukin-12 linked t...

PRINCETON, NJ / ACCESSWIRE / May 22, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that its Board of Directors has initiated a process to explore and review a range of ...

The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levels Patients have received up to 25 cycles of SON-1010 as monotherapy and 10 cycles of SON-1010 with atezolizumab (Tecentriq ® ) without dose-limiting toxicity ...

2024-05-15 09:53:32 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sonnet BioTherapeutics (NASDAQ: SONN ) just reported results for the second quarter of 2024. Sonnet BioTherapeutics reported earnings per share of 7 cents. This was below ...

2024-05-15 09:49:16 ET More on Sonnet BioTherapeutics Seeking Alpha’s Quant Rating on Sonnet BioTherapeutics Historical earnings data for Sonnet BioTherapeutics Financial information for Sonnet BioTherapeutics Read the full article on Seeking Alpha ...

Published Phase 1 data of SON-1010 in Frontiers in Immunology demonstrating the safety and tolerability of the F H AB-derived Interleukin 12 in healthy volunteers Announced early safety data from the company's Phase 1b/2a clinical trial of SON-080 in patients with chemotherapy-induced peri...

2024-05-03 13:17:33 ET More on Sonnet BioTherapeutics Seeking Alpha’s Quant Rating on Sonnet BioTherapeutics Historical earnings data for Sonnet BioTherapeutics Financial information for Sonnet BioTherapeutics Read the full article on Seeking Alpha ...